Huge biotech stocks are collectively getting hit in recent days.
BIIB has announced results on 24/10/17, beating top and bottom line expectations but stock still gap down and closed 3.9% down.
Prices fail to break above the top of the trendline measuring from Minute Wave ((a)) and reverse from the 100% fibonacci projection similarly from Minute Wave ((a)).
This is strong evidence of the relevancy of Minute Wave ((a)).
From a technical view, BIIB has seemingly completed a textbook A-B-C consolidation.
The recent high on 18/10/17 appears to be the final consolidation high.
Stock might attempt to retest this high $348.84 before continuing falling.
A successful re-test of this high will bring the stock down to its 24/06/17 low at $205.42.
A break above its recent high $348.84 will invalidate this analysis and imply a more complex consolidation on a larger scale.